Evidence grades
Regulatory status
Not approved by the FDA or any major regulator for any use; sold illegally/gray-market as an unlicensed tanning and sexual-function product (injectable vials or nasal spray). Regulators have repeatedly warned against it — an FDA warning letter (2007), the UK MHRA (2008), and Australia's TGA all flag it as unlicensed and unsafe. It is distinct from its FDA-approved melanocortin relatives — afamelanotide (Scenesse, 2019, for erythropoietic protoporphyria) and bremelanotide (Vyleesi, 2019, for HSDD) — which are different, regulated molecules. Not specifically named on the WADA Prohibited List.
Summary
Melanotan II is a synthetic peptide modeled on a natural human hormone (α-MSH) that switches on the body's pigment-making machinery. Developed at the University of Arizona in the 1990s, it activates a family of "melanocortin" receptors: one (MC1R) drives melanin production and tanning, another (MC4R) drives sexual arousal and suppresses appetite. It is sold gray-market — as injectable vials or, increasingly, nasal sprays — for tanning ("the Barbie drug"), libido, and sometimes weight loss. Unusually for a gray-market peptide, it largely does produce its two headline effects in small human studies: it tans skin with little or no UV, and it triggers erections and desire. But that is exactly why it is risky. It is not approved by any regulator, is unregulated and frequently contaminated or misdosed, and is linked in published case reports to darkening and eruption of moles, melanoma, and acute systemic toxicity. "It works" and "it's safe" are different questions, and for a drug that stimulates melanin the melanoma question is not academic.
What people use it for
People use Melanotan II mainly to get and keep a deep tan with minimal sun or tanning-bed exposure, to increase libido and erectile function, and — less commonly — for appetite suppression and fat loss. It is injected subcutaneously or used as a nasal spray, often in a "loading then maintenance" pattern, frequently combined with deliberate UV exposure to "develop" the tan. These are the claims the evidence sections test; describing them is not endorsement.
Human evidence
There is real but small-scale human evidence that Melanotan II does its two main jobs — and it is important to be precise that "it works" here means "it produces the effect," not "it is safe or wise."
Tanning. The foundational human study (Dorr et al., Life Sciences, 1996) was a tiny single-blind, placebo-controlled pilot in three healthy men who received low subcutaneous doses every other day. It produced visible tanning of the face, upper body, and buttocks without UV exposure — confirming that Melanotan II can stimulate melanin independently of sunlight. Side effects even in this small study included mild nausea, facial flushing, somnolence, and spontaneous erections accompanied by a stretching-and-yawning reflex.
Erections and sexual desire. A series of small double-blind, placebo-controlled crossover studies (Wessells and colleagues) tested Melanotan II in men. In men with psychogenic erectile dysfunction it produced erections in a large majority of doses, and in men with organic erectile dysfunction it initiated subjectively reported erections in 12 of 19 injections versus 1 of 21 placebo doses, with increased sexual desire reported after about 68% of Melanotan II doses versus 19% of placebo. Nausea and yawning were frequent, and severe nausea occurred in a meaningful minority at higher doses. These studies are the reason the molecule's MC4R activity was later developed into the FDA-approved drug bremelanotide (see Regulatory status).
The honest framing: these are small, decades-old, proof-of-concept studies, not large modern trials, and they were designed to show the effect exists — not to establish that self-injecting unregulated Melanotan II for cosmetic tanning is safe over time. A 2015 review of the literature ("An unhealthy glow?") found roughly 18 small clinical trials and 21 case reports, and concluded that while tanning and sexual effects are real, the adverse effects range from nausea and changing moles to systemic toxicity and melanoma, and long-term health outcomes are essentially undocumented.
Animal / preclinical evidence
The mechanism is well established from melanocortin-system research. As a non-selective agonist at MC1R, MC3R, MC4R, and MC5R, Melanotan II stimulates melanogenesis (the MC1R-driven tanning effect), and in rodent studies acts on MC4R pathways in the brain to reduce food intake — the basis for the appetite-suppression and "weight loss" claims. The cyclic peptide structure makes it more resistant to breakdown and more potent than natural α-MSH. This preclinical pharmacology is solid and is shared with the legitimate, approved melanocortin drugs; what it does not establish is that chronic cosmetic use in people is safe.
Anecdotal / community reports
Low-confidence. These are community reports, not evidence. Not medical guidance.
Community reports are broadly consistent with the pharmacology: users describe faster, deeper tanning, increased libido and spontaneous erections, reduced appetite, and side effects like nausea (especially early), facial flushing, and darkening of freckles and moles. Many report buying the product as a nasal spray or injectable from online vendors of unknown quality. Because the desirable effects are real and quickly visible, the risks — particularly the slow-developing skin-cancer concern — are easy to discount, which is the core problem with self-experimentation here.
Doses used in published studies
Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.
Published human studies used low subcutaneous doses on the order of 0.01–0.03 mg/kg (Dorr's tanning study escalated within that range; the erectile studies used roughly 0.025 mg/kg), administered in monitored research settings to characterize the effect. These figures are reported for context only. The "loading and maintenance" injection and nasal-spray regimens circulating online are not derived from published trials, and because the product is unregulated, the actual content and concentration of any given vial or spray is unverified. There is no approved product and no validated dose.
Safety & side effects
This is the part that matters most, because Melanotan II's effectiveness masks a genuinely concerning safety profile, and the human safety data is limited to small studies and case reports.
Common, expected effects: nausea (sometimes severe), facial flushing, yawning/stretching, spontaneous erections (with a theoretical priapism risk), decreased appetite, and generalized darkening of the skin, freckles, and existing moles.
The skin-cancer concern is the headline risk. Because Melanotan II stimulates melanocytes — the cells that can become melanoma — dermatologists have raised specific alarms. Case reports document darkening of existing moles, the rapid eruption of new and dysplastic (atypical) nevi, and changes in the size and shape of moles, and several published case reports describe melanoma arising during or shortly after melanotan use (for example, Hjuler & Lorentzen, Dermatology, 2014, in a user who also used tanning beds). This does not prove Melanotan II causes melanoma — case reports cannot establish causation, and many users also pursue UV exposure — but the biological plausibility plus the documented mole changes is why this is treated as a serious, not theoretical, concern, especially for anyone with a personal or family history of melanoma, atypical moles, or many moles. At minimum, the drug can mask the visual warning signs of skin cancer by darkening lesions.
Acute systemic toxicity is also documented. Published case reports describe a man who developed rhabdomyolysis (muscle breakdown) and kidney dysfunction after injecting Melanotan II bought online, as well as cases of renal infarction, and regulators have noted reports of kidney dysfunction and brain swelling. Add the unregulated supply chain — variable dosing, undeclared ingredients, and possible microbial contamination of injectables and sprays — and the safety picture is materially worse than the "it just gives you a tan" framing suggests. Long-term effects are unknown.
Regulatory / legal status
Melanotan II is not approved by the FDA or any major regulator for any use, and it is not a legal cosmetic or supplement. Regulators have actively warned against it: the FDA issued a warning letter to a distributor (Melanocorp) in 2007 for illegally marketing an unapproved drug; the UK MHRA warned in 2008 that it is unlicensed and unsafe and that supplying it is illegal; and Australia's TGA states it is not registered, is illegal to advertise or supply without a prescription, and has been associated with increased moles/freckles, kidney dysfunction, and brain swelling. It is sold, despite these warnings, through gray-market websites as injectable vials or nasal sprays.
A crucial point of confusion: Melanotan II is not the same as the approved melanocortin drugs that came out of the same research. Afamelanotide (Scenesse) — a different, MC1R-selective molecule given as a physician-implanted device — was FDA-approved in October 2019 to reduce phototoxicity in people with erythropoietic protoporphyria (a rare light-sensitivity disease), not for cosmetic tanning. Bremelanotide (Vyleesi) — derived from Melanotan II's MC4R activity — was FDA-approved in June 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing for gray-market Melanotan II often borrows the credibility of these approved cousins; they are regulated, studied, and indicated products, and Melanotan II is not. On the sports side, Melanotan II is not specifically named on the WADA Prohibited List (it is not primarily a performance drug), though athletes should always check the current rules. Status varies by country and can change; this is not legal advice.
Podcast / media mentions
Melanotan II's media life runs through beauty and social-media channels more than longevity podcasts. Nicknamed the "Barbie drug," it surged on TikTok and Instagram via nasal "tanning sprays" promoted by influencers, prompting public-health pushback from dermatologists and regulators (Australia's TGA, the UK's MHRA, and cancer charities have all issued warnings). The framing worth scrutinizing is the social-media pitch that it's a harmless shortcut to a tan: the tan is real, but the product is unapproved and unregulated, it can darken and multiply moles in ways that both raise melanoma concern and hide its warning signs, and it has sent users to the hospital with acute toxicity. As an academic explainer put it, you don't need the "Barbie drug" to tan, and the risks are why nearly every health authority that has looked at it says to avoid it. The critique here is of the "safe and easy" framing, not of the people drawn to it — but on this one, the regulators and dermatologists are close to unanimous.
Sources
- Dorr et al. — Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (Life Sci. 1996;58(20):1777-1784; PMID 8637402) [tanning + side effects in 3 men][human-rct]
- Hadley/Wessells — Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II (Int J Impot Res) [double-blind crossover human data on erection/desire][human-rct]
- Wessells et al. — Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (Urology. 2000;56(4):641-646; PMID 11018622)[human-rct]
- Habbema, Halk, et al. — An unhealthy glow? A review of melanotan use and associated clinical outcomes (2015; 18 clinical trials + 21 case reports reviewed)[systematic-review]
- Hjuler & Lorentzen — Melanoma Associated with the Use of Melanotan-II (Dermatology. 2014;228(1):34-36) [case report; MT-II + tanning beds preceding cutaneous melanoma][observational]
- Melanotan II: a possible cause of renal infarction — review of the literature and case report (acute systemic/vascular toxicity, incl. rhabdomyolysis reports)[observational]
- Australia TGA — Don't risk using tanning products containing melanotan (regulator warning; unlicensed; reports of moles/freckles, kidney dysfunction, brain swelling)[regulatory]
- FDA — VYLEESI (bremelanotide) FDA Approval History (approved June 21, 2019 for HSDD in premenopausal women) [an approved MT-II–derived melanocortin drug — NOT Melanotan II][regulatory]
- FDA — SCENESSE (afamelanotide) FDA Approval History (approved Oct 8, 2019 to reduce phototoxicity in erythropoietic protoporphyria) [a different, approved melanocortin drug — NOT Melanotan II][regulatory]
- The Conversation — No, you don't need the 'Barbie drug' to tan, whatever TikTok says (academic-authored public-health explainer on the MT-II social-media trend)[media]